AIM ImmunoTech Plunges 27.08% Amid Volatility Concerns

AIM ImmunoTech experienced a significant drop of 27.08% in pre-market trading on July 29, 2025, amid low-volume trade, with EPS trends under the spotlight.

AIM ImmunoTech's stock price has been influenced by recent developments in its clinical trials. The company's DURIPANC trial data showed superior survival and safety in metastatic pancreatic cancer patients, leading to a surge in its shares. This positive news has been a key driver for the stock's recent performance, highlighting the potential of the company's therapeutic approaches in the biotechnology sector.

However, the stock's volatility has also been a point of concern. AIM ImmunoTech faced a trading halt due to high volatility, which has added to the uncertainty surrounding the stock. This halt, combined with the low-volume trade, has contributed to the recent downward trend in the stock price.